Online citations, reference lists, and bibliographies.

Comparative Study Of Therapeutic Antibody Candidates Derived From Mini‐pool And Clonal Cell Lines

Lianchun Fan, Giovanni Rizzi, Kathleen K Bierilo, Jun Tian, Joon Chong Yee, Reb Russell, Tapan Kumar Das
Published 2017 · Chemistry, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
The long journey of developing a drug from initial discovery target identification to regulatory approval often leaves many patients with missed window of opportunities. Both regulatory agencies and biopharmaceutical industry continue to develop creative approaches to shorten the time of new drug development in order to deliver life-saving medicine to patients. Generally, drug substance materials to support the toxicology and early phase clinical study can only be manufactured after creating the final Master Cell Bank (MCB) of the clonally derived cell line, which normally takes 1-2 years. With recent advances in cell line development, cell culture process and analytical technologies, generating more homogeneous bulk/mini-pool population with higher productivity and acceptable quality attributes has become a norm, thereby making it possible to shorten the timeline to initiate First in Human (FIH) trial by using bulk/mini-pool generated materials to support toxicology and FIH studies. In this study, two monoclonal antibodies of different subclasses (IgG1 and IgG4) were expressed from the mini-pool cells as well as clonally derived cell lines generated from the same mini-pool. Cell growth, productivity, and product quality were compared between the materials generated from the mini-pool and clonally derived cell line. The results demonstrate the similarity of the antibody products generated from mini-pool cells and clonally derived cell lines from the same mini-pool, and strongly support the concept and feasibility of using antibody materials produced from mini-pool cultures for toxicology and FIH studies. The strategy to potentially shorten the FIH timeline is discussed. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 33:1456-1462, 2017.
This paper references
10.3109/07388551.2013.811636
Pyruvate production in Candida glabrata: manipulation and optimization of physiological function
Shubo Li (2016)
10.1002/btpr.2119
Identifying low-level sequence variants via next generation sequencing to aid stable CHO cell line screening.
Sheng S. Zhang (2015)
Breaking bottlenecks in drug discovery and development: Scientists reveal early-stage strategies for bringing safer, more effective drugs to market faster
M Larkin (2015)
Assurance of monoclonality in Biotechnol
K Evans (2015)
10.1186/s13195-016-0207-9
Drug development in Alzheimer’s disease: the path to 2025
Jeffrey L. Cummings (2016)
Breaking bottlenecks in drug discovery and development: Scientists reveal early-stage strategies for bringing safer, more effective drugs to market faster In Pharma-Biotech
M. Larkin (2015)
10.1002/cpt.502
Competitive Development in Pharmacologic Classes: Market Entry and the Timing of Development.
Joseph A DiMasi (2016)
10.4155/pbp.13.56
The use of glutamine synthetase as a selection marker: recent advances in Chinese hamster ovary cell line generation processes
Lianchun Fan (2013)
10.1002/biot.201500082
CRISPR/Cas9-mediated genome engineering of CHO cell factories: Application and perspectives.
Jae Seong Lee (2015)
Drug Administration, Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review
U. S. Foo (2017)
10.1038/nrd.2017.14
2016 FDA drug approvals
Asher Mullard (2017)
10.1038/nrd4717
Trends in breakthrough therapy designation
Rachel R. Chizkov (2015)
10.1016/j.biologicals.2010.08.004
Comparability assessments of process and product changes made during development of two different monoclonal antibodies.
Anthony S. Lubiniecki (2011)
10.1038/nrd.2016.85
Trends in clinical success rates
Katarzyna Śmietana (2016)
10.1002/btpr.2307
Generation of stable Chinese hamster ovary pools yielding antibody titers of up to 7.6 g/L using the piggyBac transposon system.
Yashas Rajendra (2016)
Industry view on the relative importance of “clonality” of biopharmaceuticalproducing cell lines. Biologicals 2016;44:117–22
C Frye (2017)
FDA drug approvals
A. Mullard (2016)
Emerging Analytical Technologies Advance Biopharma Development 2016
C. Challener (2016)
10.1002/btpr.2290
Statistical analysis of data from limiting dilution cloning to assess monoclonality in generating manufacturing cell lines.
Jorge Quiroz (2016)
10.1080/07388551.2016.1214557
Gene editing for cell engineering: trends and applications
Sanjeev Kumar Gupta (2017)
10.1016/j.biotechadv.2011.08.022
Mammalian cell protein expression for biopharmaceutical production.
Jianwei Zhu (2012)
10.1016/j.jhealeco.2016.01.012
Innovation in the pharmaceutical industry: New estimates of R&D costs.
Joseph A DiMasi (2016)
Emerging Analytical Technologies Advance Biopharma Development
C Challener (2015)
10.1002/cpt.447
The Impact of Breakthrough Therapy Designation on Development Strategies and Timelines for Nononcology Drugs and Vaccines.
Arthur Poirier (2016)
10.1021/bk-2015-1201.ch002
Sequence Variants and Sequence Variant Analysis in Biotherapeutic Proteins
Oleg V. Borisov (2015)
Food & Drug Administration, Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review
10.1002/bit.24365
Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells.
Lianchun Fan (2012)
10.1016/0021-9673(94)01255-D
Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture.
Reed J. Harris (1995)
10.1016/j.biologicals.2016.01.001
Industry view on the relative importance of "clonality" of biopharmaceutical-producing cell lines.
Christopher C. Frye (2016)
10.1002/bit.24879
Anti-cell death engineering of CHO cells: co-overexpression of Bcl-2 for apoptosis inhibition, Beclin-1 for autophagy induction.
Jae Seong Lee (2013)
10.1002/btpr.2038
Chinese hamster ovary (CHO) host cell engineering to increase sialylation of recombinant therapeutic proteins by modulating sialyltransferase expression.
Nan Lin (2015)
10.1002/btpr.2263
Genetic mutation analysis at early stages of cell line development using next generation sequencing.
Chapman Wright (2016)
10.1002/btpr.2097
Diversity in host clone performance within a Chinese hamster ovary cell line.
Peter M. O'Callaghan (2015)
10.1038/nrd.2016.19
Regulatory Watch: Impact of breakthrough therapy designation on cancer drug development
Michael B Shea (2016)
10.1016/j.biotechadv.2015.10.015
The art of CHO cell engineering: A comprehensive retrospect and future perspectives.
Simon Fischer (2015)
10.1002/btpr.2145
Assurance of monoclonality in one round of cloning through cell sorting for single cell deposition coupled with high resolution cell imaging
Krista L Evans (2015)
10.1016/j.nbt.2013.10.003
Understanding translational control mechanisms of the mTOR pathway in CHO cells by polysome profiling.
Franck C Courtes (2014)
10.1002/btpr.2108
Development and manufacturability assessment of chemically-defined medium for the production of protein therapeutics in CHO cells.
Wai Lam W. Ling (2015)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar